IDbyDNA Raises $9M in Series A Funding

idbydnaIDbyDNA, a San Francisco, CA-based precision medicine company focused on metagenomic approaches for infectious disease identification, closed $9m in Series A financing.

The round was led by Artis Ventures with participation from Arup Laboratories and other investors.

The company intends to use the funds to further develop its Taxonomer-based DNA search technologies and to launch metagenomics-based clinical tests for infectious diseases.

Founded in November 2014 by Guochun Liao, PhD, CEO, Robert Schlaberg, MD, Dr Med, MPH, Mark Yandell, PhD, and Martin Reese, PhD, IDbyDNA is developing technologies to enable universal microorganism detection by Next Generation Sequencing (NGS). This allows doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, leading to faster public health responses during infectious disease outbreaks.

Launched in May 2106, for metagenomics analysis already has registered users from more than 150 academic or government institutions and corporations.



Join the discussion